Piclozotan

From Self-sufficiency
Revision as of 10:21, 20 September 2010 by Jontas (Talk | contribs) (1 revision)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Piclozotan
File:Piclozotan.png
Systematic (IUPAC) name
3-chloro-4-[4-[4-(2-pyridinyl)-1,2,3,6-tetrahydropyridin-1-yl]butyl]-1,4-benzoxazepin-5(4H)-one
Legal status
Legal status
  • Uncontrolled
Identifiers
CAS Number 182415-09-4
PubChem CID 9801640
Chemical data
Formula C23H24ClN3O2
Molar mass 409.909 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Piclozotan (SUN-N4057) is a selective 5-HT1A receptor partial agonist, which has neuroprotective effects in animal studies.[1] It has been through early clinical trials in humans for treatment of acute stroke, but results have not yet been announced.[2][3]

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />



  1. Kamei, K.; Maeda, N.; Nomura, K.; Shibata, M.; Katsuragi-Ogino, R.; Koyama, M.; Nakajima, M.; Inoue, T.; Ohno, T. (2006). "Synthesis, SAR studies, and evaluation of 1,4-benzoxazepine derivatives as selective 5-HT1A receptor agonists with neuroprotective effect: Discovery of Piclozotan". Bioorganic & medicinal chemistry. 14 (6): 1978–1992. doi:10.1016/j.bmc.2005.10.046. PMID 16290165.  edit
  2. Ferro, J.; Dávalos, A. (2006). "Other neuroprotective therapies on trial in acute stroke". Cerebrovascular diseases (Basel, Switzerland). 21 Suppl 2: 127–130. doi:10.1159/000091712. PMID 16651823.  edit
  3. Mondick, J.; Oo, C.; Patel, D.; Fujitani, T.; Shimizu, K.; Barrett, J. (2009). "Population pharmacokinetics of the selective serotonin 5-HT1A receptor partial agonist piclozotan". American journal of therapeutics. 16 (2): 106–115. doi:10.1097/MJT.0b013e31816b8c85. PMID 19300037.  edit